KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Adaptive Biotechnologies (ADPT) EPS (Weighted Average and Diluted) (2020 - 2025)

Adaptive Biotechnologies' EPS (Weighted Average and Diluted) history spans 6 years, with the latest figure at -$0.08 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 63.64% year-over-year to -$0.08; the TTM value through Dec 2025 reached -$0.39, up 63.89%, while the annual FY2025 figure was -$0.39, 63.89% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.08 at Adaptive Biotechnologies, down from $0.06 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.06 in Q3 2025 and bottomed at -$0.48 in Q4 2023.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$0.33 (2023), against an average of -$0.3.
  • The largest annual shift saw EPS (Weighted Average and Diluted) tumbled 77.78% in 2023 before it soared 127.27% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.44 in 2021, then skyrocketed by 38.64% to -$0.27 in 2022, then plummeted by 77.78% to -$0.48 in 2023, then skyrocketed by 54.17% to -$0.22 in 2024, then surged by 63.64% to -$0.08 in 2025.
  • Per Business Quant, the three most recent readings for ADPT's EPS (Weighted Average and Diluted) are -$0.08 (Q4 2025), $0.06 (Q3 2025), and -$0.17 (Q2 2025).